Center for Translational Pain Medicine, Department of Anesthesiology, and Departments of Neurobiology and Cell Biology, Duke University Medical Center, Durham, North Carolina, USA; email:
Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:273-293. doi: 10.1146/annurev-pharmtox-051921-084047. Epub 2022 Sep 13.
Specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins, are endogenous lipid mediators that are synthesized from omega-3 polyunsaturated fatty acids during the acute phase or resolution phase of inflammation. Synthetic SPMs possess broad safety profiles and exhibit potent actions in resolving inflammation in preclinical models. Accumulating evidence in the past decade has demonstrated powerful analgesia of exogenous SPMs in rodent models of inflammatory, neuropathic, and cancer pain. Furthermore, endogenous SPMs are produced by sham surgery and neuromodulation (e.g., vagus nerve stimulation). SPMs produce their beneficial actions through multiple G protein-coupled receptors, expressed by immune cells, glial cells, and neurons. Notably, loss of SPM receptors impairs the resolution of pain. I also highlight the emerging role of SPMs in the control of itch. Pharmacological targeting of SPMs or SPM receptors has the potential to lead to novel therapeutics for pain and itch as emerging approaches in resolution pharmacology.
特异性促解决介质(SPM),包括 resolvins、保护素和maresins,是内源性脂质介质,在炎症的急性期或消退期由 omega-3 多不饱和脂肪酸合成。合成的 SPM 具有广泛的安全性,在临床前模型中表现出强大的抗炎作用。过去十年的累积证据表明,外源性 SPM 在炎症性、神经性和癌性疼痛的啮齿动物模型中具有强大的镇痛作用。此外,内源性 SPM 由假手术和神经调节(例如,迷走神经刺激)产生。SPM 通过表达于免疫细胞、神经胶质细胞和神经元上的多种 G 蛋白偶联受体发挥其有益作用。值得注意的是,SPM 受体的缺失会损害疼痛的消退。我还强调了 SPM 在控制瘙痒中的新作用。SPM 或 SPM 受体的药物靶向有可能为疼痛和瘙痒带来新的治疗方法,成为解决药理学中的新兴方法。